<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Drospirenone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01395</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Drospirenone is a synthetic progestin that is an analog to spironolactone. It is found in a number of birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. It was shown in animal studies that drospirenone exhibits antiandrogenic activity judging from accessory sex gland growth in castrated, androgen-treated, juvenile rats.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01395/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01395/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01395.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01395.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01395.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01395.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01395.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01395">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>6&#946;,7&#946;,15&#946;,16&#946;-dimethylene-3-oxo-17&#945;-pregn-4-ene-21,17 carbolactone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Drospirenona</td><td>Spanish</td><td>INN</td></tr><tr><td>Drospirenonum</td><td>Latin</td><td>INN</td></tr><tr><td>DRSP</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Safyral</td><td>Bayer HealthCare Pharmaceuticals Inc.</td></tr><tr><td>Yasmin</td><td>Bayer HealthCare Pharmaceuticals Inc.</td></tr><tr><td>Yaz </td><td>Bayer HealthCare Pharmaceuticals Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Safyral</td><td>drospirenone + ethinyl estradiol + levomefolate calcium + levomefolate calcium</td></tr><tr><td>Yasmin</td><td>drospirenone + ethinylestradiol</td></tr><tr><td>Yaz</td><td>drospirenone + ethinylestradiol</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/mineralocorticoid-receptor-antagonists">Mineralocorticoid Receptor Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>67392-87-4</td></tr><tr><th>Weight</th><td>Average: 366.4932<br>Monoisotopic: 366.219494826</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>30</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>METQSPRSQINEEU-HXCATZOESA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0^{2,4}.0^{5,10}.0^{14,19}.0^{16,18}]nonadecane-15,2'-oxolan]-5-ene-5',7-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01395.gif?1371076603">show</a>(37.1 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Steroid Lactones</td></tr><tr><th>Direct parent</th><td>Steroid Lactones</td></tr><tr><th>Alternative parents</th><td>Estrogens and Derivatives; Other Steroids and Derivatives; Tetrahydrofurans; Oxolanes; Ketones; Lactones; Carboxylic Acid Esters; Polyamines</td></tr><tr><th>Substituents</th><td>estrane-skeleton; other-steroid-skeleton; gamma butyrolactone; oxolane; tetrahydrofuran; lactone; ketone; carboxylic acid ester; polyamine; carboxylic acid derivative; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the steroid lactones. These are sterol lipids containing a lactone moiety linked to the steroid skeleton.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prevention of pregnancy in women who elect an oral contraceptive.</td></tr><tr><th>Pharmacodynamics</th><td>Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic.</td></tr><tr><th>Mechanism of action</th><td>Progestins such as drospirenone diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.</td></tr><tr><th>Absorption</th><td>Oral bioavailability is approximately 76%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>95-97%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Extensively metabolized following oral or intravenous administration. The two major metabolites are inactive and are formed independent of the CYP450 enzyme system. The metabolites are the acid form of drospirenone formed by opening of the lactone ring and the 4,5-dihydro-drospirenone-3-sulfate. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Drospirenone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00741">4,5-dihydro-drospirenone-3-sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/762">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>30 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9383</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6376</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6524</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6171</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6726</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7005</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6964</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5534</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8665</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9336</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7754</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8355</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8541</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9163
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9505
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9757
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.9430 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9393
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8215
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>0.451 mg levomefolate calcium</td></tr><tr><td>Tablet</td><td>Oral</td><td>3 mg drospirenone (DRSP), 0.03 mg ethinyl estradiol (EE) as betadex clathrate and 0.451 mg levomefol</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Artemether may decrease the effectiveness of drospirinone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.</td></tr><tr><td><a href="/drugs/DB00542">Benazepril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00307">Bexarotene</a></td><td>Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of drospirenone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00796">Candesartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01197">Captopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01340">Cilazapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. </td></tr><tr><td><a href="/drugs/DB00584">Enalapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00876">Eprosartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00492">Fosinopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01109">Heparin</a></td><td>Heparin can increase risk of hyperkalemia for patients on drospirenone</td></tr><tr><td><a href="/drugs/DB01029">Irbesartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00722">Lisinopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00678">Losartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00275">Olmesartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00790">Perindopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00881">Quinapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00178">Ramipril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Telmisartan may increase the hyperkalemic effect of Drospirenone. Monitor for increased serum potassium concentrations during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>Thiopental may decrease the effect of Drospirenone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Drospirenone. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00384">Triamterene</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Drospirenone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if drospirenone is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food reduces the rate of absorption, but not the extent of absorption. </li></ul></td></tr></tbody></table>